Express Pharma

Gilead and Merck initiate phase-II study on Lenacapavir and Islatravir oral combo for HIV-1 treatment in virologically suppressed adults

This clinical study is the first from Merck and Gilead’s collaboration to develop potential long-acting HIV treatment options